Millennium Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-29,700
Closed -$3.92M 6504
2025
Q1
$3.92M Buy
+29,700
New +$3.7M ﹤0.01% 3102
2023
Q2
Sell
-20,000
Closed -$1.08M 6810
2023
Q1
$1.08M Buy
+20,000
New +$967K ﹤0.01% 4015
2022
Q4
Sell
-20,400
Closed -$949K 7164
2022
Q3
$949K Sell
20,400
-29,600
-59% -$1.55M ﹤0.01% 4386
2022
Q2
$2.85M Buy
+50,000
New +$2.83M ﹤0.01% 3356
2022
Q1
Sell
-37,500
Closed -$1.96M 7622
2021
Q4
$1.96M Buy
+37,500
New +$1.58M ﹤0.01% 3801
2020
Q4
Sell
-50,000
Closed -$1.28K 5665
2020
Q3
$1.28K Buy
50,000
+25,000
+100% +$570K ﹤0.01% 2952
2020
Q2
$642K Buy
+25,000
New +$506K ﹤0.01% 3253
2020
Q1
Sell
-350,000
Closed -$12M 4622
2019
Q4
$12M Buy
+350,000
New +$4.2M 0.02% 1227
2019
Q2
Sell
-137,500
Closed -$1.68M 4551
2019
Q1
$1.68M Buy
+137,500
New +$1.76M ﹤0.01% 2525
2018
Q4
Sell
-271,300
Closed -$5.89M 4265
2018
Q3
$5.89M Buy
271,300
+21,300
+9% +$445K 0.01% 1682
2018
Q2
$4.42M Buy
250,000
+50,000
+25% +$1.02M 0.01% 1891
2018
Q1
$4.21M Buy
+200,000
New +$3.9M 0.01% 1913
2017
Q4
Sell
-150,000
Closed -$2.37M 4135
2017
Q3
$2.37M Buy
+150,000
New +$2.2M ﹤0.01% 2082
2016
Q4
Sell
-150,000
Closed -$2.29M 3821
2016
Q3
$2.29M Buy
+150,000
New +$6.07M ﹤0.01% 1869
2016
Q2
Sell
-100,000
Closed -$2.78M 3667
2016
Q1
$2.78M Sell
100,000
-25,000
-20% -$833K 0.01% 1607
2015
Q4
$6.72M Buy
+125,000
New +$6.31M 0.01% 1164

Other funds holding ITCI

Millennium Management's ITCI Position: Q2 2025 in Review

Millennium Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 844,073 shares — an estimated $111M sold.

Millennium Management first reported a position in ITCI in Q1 2014 and held it in 41 quarters. The position peaked at $111M in Q1 2025. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

  • Millennium Management reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
  • Millennium Management sold 844,073 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $111M.
  • Millennium Management first reported a position in Intra-Cellular Therapies Inc. in Q1 2014 and held it in 41 quarters.
  • Millennium Management's Intra-Cellular Therapies Inc. position peaked at $111M in Q1 2025.
  • 4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Millennium Management's 13F filing for Q2 2025, filed 14 Aug 2025.